Compare Sanofi SA (SNY) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Xylem, Inc. — how do they compare? Sanofi SA trades at $42.7 (market cap $104.06B), while Xylem, Inc. trades at $107.97 (market cap $25.41B). The key difference: Sanofi SA is far larger — about 4.1× Xylem, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SNY | XYL | |
|---|---|---|
Market Cap | $104.06B | $25.41B |
Sector | Health | Industrials |
52-Week High | $52.34 | $152.95 |
52-Week Low | $41.33 | $105.69 |
Enterprise Value | $124.09B | $27.18B |
Dividend Yield | 5.61% | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
XYL trades at $108.81, up 2.95% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 10.59% net margin. Recent news highlights strategic acquisitions, a new CFO appointment, and a dividend declaration, supporting growth in water technology sectors. The stock shows resilience with revenue growth from $5.5B in 2022 to $9.04B in 2025, though it faces near-term resistance.
Outlook is cautiously optimistic with a consensus price target of $152.29 implying 40% upside, driven by margin expansion and AI-driven demand. Risks include execution of acquisitions and market volatility, but analyst sentiment leans buy/hold with low sell ratings. The stock presents a value opportunity for long-term investors focused on sustainable water solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
